Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130996 | 0.80 | GRM5 (0.47) | GRM5FFAR1FFAR4 | |
| SCHEMBL10131003 | 0.77 | GRM5 (0.54) | GRM5FFAR1FFAR4APP | |
| SCHEMBL30833070 | 0.77 | GRM5 (0.54) | GRM5FFAR1FFAR4APPCYP1A2 | |
| SCHEMBL10131004 | 0.77 | GRM5 (0.54) | GRM5FFAR1FFAR4APP | |
| SCHEMBL6595034 | 0.77 | GRM5 (0.54) | GRM5FFAR1FFAR4APP | |
| SCHEMBL3955825 | 0.77 | GRM5 (0.54) | GRM5FFAR1FFAR4APPCYP1A2 | |
| SCHEMBL5886608 | 0.76 | APP (0.71) | GRM5FFAR1APPCYP1A1CYP1A2 | |
| SCHEMBL5219755 | 0.76 | RAB9A (0.45) | — | |
| SCHEMBL31588411 | 0.76 | CHEK1 (0.63) | — | |
| SCHEMBL70602 | 0.76 | CHEK1 (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046232-A1 | COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2012-02-23 | — | — | US | disclosed |
| US-7531541-B2 | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders | VANDERBILT UNIVERSITY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20070208028-A1 | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders | VANDERBILT UNIVERSITY | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046232-A1 | COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR | GRM6, GRM5, GRM7 | GRM5 2/4885FFAR1 1932/4885FFAR4 2197/4885 |
| US-20070208028-A1 | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders | GRM5, GRIK5, GRM1 | GRM5 1/4885FFAR1 210/4885FFAR4 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.